Beigene Ltd (NASDAQ:BGNE) CEO John Oyler sold 31,989 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was sold at an average price of $39.39, for a total transaction of $1,260,046.71. Following the completion of the sale, the chief executive officer now owns 197,640 shares in the company, valued at approximately $7,785,039.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
John Oyler also recently made the following trade(s):
- On Monday, March 6th, John Oyler sold 108,999 shares of Beigene stock. The stock was sold at an average price of $40.91, for a total transaction of $4,459,149.09.
- On Tuesday, February 21st, John Oyler sold 64,963 shares of Beigene stock. The stock was sold at an average price of $40.55, for a total transaction of $2,634,249.65.
Shares of Beigene Ltd (NASDAQ:BGNE) traded up 0.03% during midday trading on Monday, hitting $39.56. 95,629 shares of the stock traded hands. Beigene Ltd has a 12-month low of $24.53 and a 12-month high of $41.89. The company’s market capitalization is $1.30 billion. The firm’s 50 day moving average price is $38.21 and its 200 day moving average price is $33.14.
Your IP Address:
A number of institutional investors have recently added to or reduced their stakes in BGNE. Baillie Gifford & Co. increased its position in Beigene by 0.7% in the fourth quarter. Baillie Gifford & Co. now owns 69,284 shares of the company’s stock worth $2,103,000 after buying an additional 449 shares during the period. State Street Corp increased its position in Beigene by 6.0% in the fourth quarter. State Street Corp now owns 33,769 shares of the company’s stock worth $1,025,000 after buying an additional 1,917 shares during the period. Vident Investment Advisory LLC increased its position in Beigene by 9.7% in the fourth quarter. Vident Investment Advisory LLC now owns 24,958 shares of the company’s stock worth $758,000 after buying an additional 2,207 shares during the period. Susquehanna International Group LLP purchased a new position in Beigene during the third quarter worth $455,000. Finally, Norges Bank purchased a new position in Beigene during the fourth quarter worth $607,000. 33.01% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently issued reports on the stock. Maxim Group set a $52.00 price objective on shares of Beigene and gave the stock a “buy” rating in a research note on Thursday, March 2nd. Zacks Investment Research downgraded shares of Beigene from a “buy” rating to a “hold” rating in a research note on Tuesday, January 17th.
Beigene Company Profile
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/john-oyler-sells-31989-shares-of-beigene-ltd-bgne-stock/1709359.html
Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.